BALB/c mice immunized with syngeneic methylcholanthrene-induced fibrosarcomas did not have antibodies against the unique tumor-specific transplantation antigens, even though they were capable of rejecting a lethal dose of tumor cells. Endogenous murine leukemia virus antigens expressed by certain of the tumors did, however, elicit high titers of antibodies, accounting for serological crossreactions that occurred between those tumors.
Chemically induced neoplasms express tumor-specific transplantation antigens (TSTA), which can cause the rejection of an otherwise lethal challenge of syngeneic tumor cells by animals that had been immunized with the respective tumor. Immunization with other neoplasms of similar origin is ineffective, since the TSTA are unique for each tumor (1, 2) . Serological investigations of the TSTA have been relatively unfruitful, because sera from tumor immune mice have often been unreactive or have crossreacted with several tumors (3) (4) (5) (6) . This has hampered progress in elucidating the immunochemical structure of the TSTA.
An explanation of the discrepancy between transplantation and serological studies may lie in the expression of endogenous viral antigens by some chemically induced neoplasms. Murine leukemia virus (MuLV) exists as a genetic infection in all mice (7, 8) , and although genes of these endogenous viruses are not normally expressed in young adults of low leukemic strains (9) (10) (11) (12) , MuLV antigens can often be detected in chemically induced tumors (13, 14) . Since mice of most strains are able to make antibodies against envelope antigens of their endogenous MuLV (15) (16) (17) , it is conceivable that the crossreacting antibodies formed against chemically induced tumors are, in fact, a response to MuLV antigens that are expressed by some of them.
The purpose of this study was to examine the humoral immune response of mice to chemically induced tumors and to determine whether antibodies were (13, 14) .
Tumors. Fibrosarcomas were induced by intramuscular injection of 2-month-old mice with 0.1 mg of 3-methylcholanthrene suspended in trioctanoin. These tumors were maintained in vvo by serial transplantation to mice of the same sex as the animal in which the respective tumors originated. Tumors were also grown in vitro as adherent monolayers; the culture methods have been described (18) .
Radioimmunoassay of p30. Sarcomas were tested by competition radioimmunoassays for p30 (19) , the major core protein of MuLV. These assays were performed with 125I-labeled Rauscher MuLV p30 and a monospecific goat antiserum raised against the antigen. Tumor extracts were prepared by homogenization, sonication, and freeze-thawing in radioimmunoassay buffer, Tris-HCl (20 mM, pH 7.6)/NaCl (100 mM)/ EDTA (1 mM)/bovine serum albumin (20 g/liter)/Nonidet P-40 (10 g/liter). The radioimmunoassay incubation mixture contained serial dilutions of tumor extract or tissue culture medium (20 ,ul) , 125I-labeled p30 (5000 cpm in 20 ,A), and goat antiserum against p30 (20 ,l of 1/50,0oo dilution), all in radioimmunoassay buffer. After 1 hr at 370, antigen complexed with antibody was removed with an immunoadsorbent of Staphylococcus aureus that had been incubated with rabbit antiserum against goat immunoglobulin. The amount of 125I-labeled p30 precipitated was determined with a gamma counter. The assay was calibrated with a standard solution of purified Rauscher MuLV p30 obtained from the Viral Oncology Program, National Cancer Institute.
Antisera. Goat antiserum (5S-167) against purified gp7O of Rauscher MuLV was obtained from the Viral Oncology Program, National Cancer Institute. In radioimmunoassay this serum had a titer of 6400 against gp7O and a titer of 200 against p30. Goat antiserum (6S-492) against purified p30 of Rauscher MuLV had a titer of 38,000 against p30 and a titer of 40 against gp7O.
Assays for Reverse Transcriptase (RNA-Directed DNA nucleotidyltransferase). Assays of reverse transcriptase activity were performed as described (20, 21) . Pelleted MuLV was Abbreviations: TSTA, tumor-specific transplantation antigen; MuLV, murine leukemic virus; l25I-protein A, l25I-labeled protein A.
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A complement-dependent cytotoxicity assay was also used. 40 . In order to saturate the remaining nonspecific proteinadsorbing sites in the plastic wells, the plates were then incubated overnight with phosphate-buffered saline containing bovine serum albumin (10 g/liter) and sodium azide (1 g/liter). Antibodies to viral proteins were detected by sequential incubations for 1 hr at 370 with (a) 25 Ml of diluted antiserum followed by two washes with the above buffer, and (b) 25 Ml of 52I-protein A (105 cpm), followed by two washes. 125I-Protein A bound to the viral proteins was eluted with 2 M NaOH.
Radioimmunoprecipitation Assays. Tumor cells were surface-labeled with 125I in the presence of chloramine-T (L. Rohrschneider, unpublished data), solubilized in radioimmunoassay buffer, and incubated with antiserum (10 Ml) for 1 hr at 00. Immune complexes were removed by incubation with S. aureus (5 mg) for 30 min at 0°and centrifugation, and then analyzed by sodium dodecyl sulfate gel electrophoresis (23) . (Table 2) . Although an extensive search was made, the sera of mice that were immunized with tumors not expressing MuLV were uniformly negative, with cytotoxic titers of less than 40. On the other hand, sera from mice that were immunized with some of the tumors that expressed MuLV contained antibodies that bound to tumor cells expressing gp7O; these same sera were invariably negative when tested on tumor cells that did not express gp7O. In some cases the cytotoxic titers of the reactive sera on virus-producing tumors were as high as 40,000. A single exception to this finding was tumor 1422, which was sensitive to the goat antiserum against gp7O but did not react with mouse antisera that were prepared against virusproducing tumors.
RESULTS

Expression of MuLV in methylcholanthrene-induced
The occurrence of antiviral antibodies in the sera of mice that were immunized with virus-producing tumors was demonstrated directly by 125I-protein A assays performed with MuLV purified by density gradient centrifugation (14) . Reactions 
DISCUSSION
Several conclusions concerning chemically induced sarcomas of BALB/c mice can be drawn from the present data. First, primary tumors rarely expressed detectable MuLV antigens, whereas tumors that had been repeatedly transplanted in syngeneic mice commonly produced MuLV and expressed viral antigens at the cell surface. Preliminary studies suggest that several antigenically distinct viruses were activated in these tumors. Thus, tumor 1422 reacted with goat antiserum against gp7O but not with mouse antisera that were prepared against virus-producing tumors. It was presumed that the mouse antisera reacted primarily with type-specific antigens of gp7O. The reason why most sarcomas that had been serially transplanted through several passages expressed MuLV antigens is not clear. It We realize that the demonstration of an immune response to a tumor, or lack thereof, is predicated on the sensitivity of the immunological assay used in the analysis. As a general principle it is unwise to conclude nonimmunogenicity on the basis of negative findings. Nevertheless, the findings that antibody titers as high as 40,000 are elicted against MuLV antigens but not against TSTA suggests that the TSTA do not easily elicit antibody formation. In this respect, the TSTA are similar to the lymphocyte-defined antigens of the major histocompatibility complex (24) (25) (26) .
Last, the observation that mice immune to chemically induced sarcomas had antibodies to MuLV antigens but not to TSTA could account for the disagreement between transplantation and serological studies (3) (4) (5) (6) . In the light of these findings, it may be necessary to re-evaluate previous reports of common fetal or sarcoma antigens in these tumors (3) (4) (5) (6) .
